Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Appointed director
|
|
HOOKIPA Pharma Inc. (HOOK)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/10/2023 |
SC TO-I
| Form SC TO-I - Tender offer statement by Issuer: |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
8-K
| Quarterly results |
| 08/04/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 06/09/2023 |
8-K
| Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits Interactive Data |
| 06/01/2023 |
8-K
| Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other E...|
Docs:
|
"UNDERWRITING AGREEMENT",
"HOOKIPA PHARMA INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A-2 CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW HOOKIPA PHARMA INC., a Delaware corporation , in accordance with the provisions of Section 103 of the Delaware General Corporation Law does hereby certify that, in accordance with Sections 141 and 151 of the DGCL, the following resolution was duly adopted by a committee of the Board of Directors of the Corporation on May 30, 2023: RESOLVED, pursuant to authority expressly set forth in the Amended and Restated Certificate of Incorporation of the Corporation , the issuance of a series of Preferred Stock designated as the Series A-2 Convertible Preferred Stock, par value $0.0001 per share, of the Corpora...",
"The New York Times Building",
"HOOKIPA Pharma Announces Pricing of $50.0 Million Public Offering of Common Stock and Non-Voting Convertible Preferred Stock NEW YORK and VIENNA, Austria, May 31, 2023 – HOOKIPA Pharma Inc. , a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the pricing of an underwritten public offering of 22,900,768 shares of its common stock and 15,268 shares of its non-voting Series A-2 convertible preferred stock . The public offering price of each share of common stock is $1.31 and the public offering price of each share of non-voting Series A-2 preferred stock is $1,310.00 . The gross proceeds to HOOKIPA from this offering are expected to be approximately $50.0 million, before deducting underwriting discounts and commissions and othe..." |
|
| 06/01/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 05/31/2023 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/11/2023 |
8-K
| Quarterly results |
| 04/13/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 04/13/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/13/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/15/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/15/2023 |
8-K
| Quarterly results |
| 03/13/2023 |
8-K
| Appointed a new director|
Docs:
|
"HOOKIPA Pharma Appoints Terry Coelho to its Board of Directors New York, US and Vienna, Austria, March 13, 2023 - HOOKIPA Pharma Inc. , a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced today that Terry Coelho will join its Board of Directors, Audit Committee and Compensation Committee, effective April 3, 2023. “Terry is an immensely valuable addition to our Board, given her experience in business strategy, broad financial transactions and business development, and we are thrilled to welcome her to the team,” said Joern Aldag, Chief Executive Officer at HOOKIPA. “Terry has worked with companies large and small and navigated fast-paced, complex business environments, including in the pharmaceutical sector. We will undoubtedly bene..." |
|
| 02/14/2023 |
SC 13G
| BAKER BROS. ADVISORS LP reports a 6.6% stake in HOOKIPA Pharma Inc. |
| 02/14/2023 |
SC 13G/A
| GILEAD SCIENCES, INC. reports a 7.2% stake in HOOKIPA PHARMA INC. |
| 02/14/2023 |
SC 13G/A
| EcoR1 Capital, LLC reports a 9.1% stake in Hookipa Pharma Inc. |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/13/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 02/09/2023 |
SC 13G/A
| FMR LLC reports a 9.5% stake in HOOKIPA PHARMA INC |
| 01/20/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 12/15/2022 |
8-K
| Quarterly results |
| 11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/14/2022 |
8-K
| Quarterly results |
| 10/20/2022 |
8-K
| Quarterly results |
| 08/11/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/11/2022 |
8-K
| Quarterly results |
| 07/22/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 07/18/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 07/12/2022 |
DEL AM
| Form DEL AM - Delaying amendment: |
| 07/12/2022 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 07/11/2022 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
|
|
|